San Francisco Bay Area biotech stories.
Thursday, July 26, 2012
Researchers launch two cancer trials with Exelixis' 'cabo'
Exelixis CEO Michael Morrissey.
Researchers at Memorial Sloan Kettering Cancer Center and
Massachusetts General Hospital
have launched separate trials using
experimental cancer-fighting drug cabozantinib.
South San Francisco-based Exelixis (NASDAQ: EXEL)
, a lung cancer specialist at Memorial Sloan-Kettering Cancer Center in New York, is working on a Phase II trial in non-small cell lung cancer patients. Also,
of Massachusetts General Hospital in Boston, is conducting a pilot Phase I trial in patients with relapsed or refractory multiple myeloma.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)